A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC

The purpose of this study is to evaluate the pharmacokinetic (PK) profile, safety, and efficacy of tislelizumab administered once every 2 weeks (Q2W) or once every 4 weeks (Q4W) in combination with chemotherapy as first-line treatment in Japanese participants with previously untreated, unresectable locally advanced, or metastatic esophageal squamous cell carcinoma (ESCC).

Trial Details

NCT ID
NCT07733180
Phase
PHASE2
Sponsor
BeOne Medicines
Status
RECRUITING
Cancer Type
Esophageal Cancer
Interventions
  • Tislelizumab
  • Oxaliplatin
  • Leucovorin
  • 5-fluorouracil (5-FU)
Locations (sample)
  • Yokohama, Kanagawa, Japan|35.43333,139.65
  • Takatsukishi, Osaka, Japan
  • ChuoKu, Tokyo, Japan
  • Osaka, Japan|34.69379,135.50107

Key Eligibility Criteria

  • Able to provide written informed consent by the participant or by the participants' legally acceptable representative and can understand and agree …
  • Histologically confirmed, unresectable locally advanced, recurrent or metastatic ESCC not amenable to curative approaches such as definitive chemor…
  • No previous systemic therapy for unresectable locally advanced, recurrent or metastatic ESCC
  • At least 1 measurable lesion per RECIST v1.1 as determined by investigator

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Esophageal Cancer Trials on Trialify →